MM

Matthew McAviney

Partner at New Enterprise Associates (NEA)

San Francisco, California

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $2,000,000.00

  • Max Investment:

    $50,000,000.00

  • Target Investment:

    $25,000,000.00

Skills

Financial Modeling
Lifesciences
Biotechnology
Valuation
Equity Research
Corporate Development
Venture Capital
Business Development
Strategy
Medicine
Biopharmaceuticals

Education

Investments

AviadoBio

Series A

Total Funding: $78M

Sagimet Biosciences

Series Unknown

Total Funding: $190M

Work Experience

New Enterprise Associates (NEA)

2018

  • Partner

    2018

    Biopharma

F-Prime Capital

2013 - 2018

  • Principal

    2013 - 2018

    Biopharma Portfolio companies: Apellis, Avalyn, Denali, Iora, Modis, Semma, Surface, Unum

Oliver Wyman

2012 - 2013

  • Associate, Health & Life Sciences Practice

    2012 - 2013

    Healthcare strategy and due diligence engagements

Robert W. Baird & Co.

2011 - 2012

  • Senior Equity Research Associate, Biotechnology

    2011 - 2012

    Senior Analyst: Chris Raymond Sample coverage list: Amgen, Biogen, Celgene, Alexion, Regeneron, Biomarin, Onyx, Tesaro, Human Genome Sciences, Amag, Dendreon, Endocyte, New Link Genetics